Bogotá D.C. lunes, 23 de mayo de 2016

Respetado Ministro:

Remito para su conocimiento y fines pertinentes la comunicación suscrita por 132 profesionales abogados, economistas y académicos, quienes apoyan la propuesta del Gobierno Nacional de declarar el medicamento para el cáncer IMATINIB como de interés público bajo condiciones de competencia, ello justificado en normas internacionales que habilitan al país para emitir licencias obligatorias sobre patentes otorgadas a los medicamentos.

Cordial saludo,

ENRIQUE RIVEIRA BORNACELLI
Secretario Privado

Anexo: (8 hojas)
MCRCH
May 16th 2016

Mr. President

JUAN MANUEL SANTOS
President of the Republic of Colombia

SUBJECT: Colombia’s Right to Issue a Compulsory License for the Cancer Medicine Imatinib

Dear President Santos,

We are lawyers, academics and other experts specializing in fields including intellectual property, trade and health, writing to affirm that international law and policy support Colombia’s right to issue compulsory licenses on patents in order to promote public interests including access to affordable medicines.

Colombia’s Ministry of Health and Social Protection has proposed to declare access to the cancer medicine imatinib under competitive conditions to be a matter of public interest. A public interest declaration should lead to the grant of a compulsory license on a patent held by Novartis, facilitating generic competition and reducing prices. We encourage your administration, the Ministry of Health and the Superintendency of Industry and Trade to proceed with the public interest declaration.

Recent media reports suggest that staff for the U.S. Senate Finance Committee and potentially representatives of the U.S. government may have communicated incorrect beliefs about compulsory licensing to their Colombian counterparts.¹ If the reports are accurate, those officials have acted inappropriately, and contravened U.S. government policy, which supports trading partners’ rights to issue compulsory licenses. We condemn any pressure levied against Colombia for its use of lawful policies such as compulsory licensing to promote public health.

Article 31 of the World Trade Organization’s Agreement on Trade-Related Aspects of Intellectual Property (WTO’s TRIPS) permits all WTO members, including Colombia, to issue compulsory licenses at any time on grounds of their choosing². The only compensation due to patent-holders in instances of compulsory licensing is a reasonable royalty, which governments may determine at their discretion³.

¹ See http://www.cisopactador.com/noticias/salud/presidn-de-eeuu-colombia-un-reple-el-precio-del-imat-article-531535 and
³ Id. Art. 31 (h)
The WTO’s Declaration on the TRIPS Agreement and Public Health affirms this interpretation of Article 31 and its importance to health. The “Doha Declaration” explicitly recognizes the impact of intellectual property on medicine prices and states that countries’ patent obligations under WTO rules “should be interpreted and implemented in a manner supportive of WTO members’ right to protect public health and, in particular, to promote access to medicines for all.”

The issuance of a compulsory license on imatinib is entirely consistent with the terms of trade and investment agreements to which Colombia is a party. The U.S. “May 10th Agreement” of 2007, for example, expressly incorporated certain public health safeguards in the U.S.-Colombia Trade Promotion Agreement and preserved Colombia’s right to issue licenses for patented inventions.

High prices for any important medicine impose a burden on the public health system responsible for providing it, and lead to the rationing of treatment and other health services. When a pharmaceutical company uses a patent to exclude competition, it can charge much higher prices.

A recent report by Colombia’s Ministry of Health and Social Protection specifies considerable predicted cost savings through a compulsory license for imatinib. The report of the ministry’s Technical Committee for the Public Interest Declaration states:

...The impact on health system financing of only a single manufacturer supplying imatinib in the market is important. Additionally, prices of Glivec, despite being subject to controls, are still very high compared with generics, which have been progressively leaving the market with the grant of the patent. Direct price controls ... will never match the results achieved by competition in the market. Without a doubt, the best way to reduce prices is competition.

Novartis has rejected the Colombian government’s offer to negotiate a price reduction for imatinib.

---

Issuing a compulsory license does not expropriate the property rights of the patent holder. Rather, the right of a government to authorize other uses of a patented invention is embedded and reserved in the grant of a patent. Furthermore, a license does not prevent the patent holder from continuing to sell its product, prohibit non-licensed uses of the invention, or prohibit non-licensed parties from using the invention.

We hope this letter will support Colombia’s ongoing efforts to increase access to affordable medicines and put to rest any concerns regarding the international legitimacy of compulsory licensing. Compulsory licensing is a key tool for protecting the financial stability of health systems and ensuring access to medicines and health services for all.

Sincerely,

Dr. Deborah Gleeson  
School of Psychology and Public Health,  
La Trobe University, Australia

Amy Kapczynski  
Professor of Law  
Yale Law School  
USA

Andrew S. Goldman  
Counsel, Policy and Legal Affairs  
Knowledge Ecology International  
USA

Suerie Moon  
Harvard T.H. Chan School of Public Health and Kennedy School of Gov.  
USA

Warren Kaplan, PhD, JD, MPH  
WHO Collaborating Center for Pharmaceutical Policy  
Center for Global H & D. Boston

Peter Maybarduk  
Global Access to Medicines Program  
Director Public Citizen  
USA

Prof. Dr. H. Schellekens MD,PhD  
Director WHO Utrecht Center of Excellence for Affordable Biopharmaceuticals  
Utrecht University

Professor Brook K. Baker  
Northeastern University School of Law Program on Human Rights and the Global Economy Honorary Research USA

Luz M. Umbasia B.  
Attorney Administrative Law Specialist  
MSC (C) International Relations & Business UMNG Colombia

Rachel Kiddell-Monroe LL.M  
Professor of Practice  
McGill University, Montreal, Quebec

Joel Lexchin MD  
School of Health Policy & Management  
York University  
Canadá

Sean Flynn  
Program on Information Justice and Intellectual Property  
American University Washington USA
Dipl. Soz Hedwig Diekwisch
Managing Director
BUKO Pharma-Kampagne / Germany

Robert Weissman
President Public Citizen
Washington D.C. USA

Rochelle Dreyfuss
Pauline Newman Professor of Law
Co-Director of the Engelberg Center on Innovation Law and Policy
New York University School of Law

Ellen 't Hoen
Consultant Medicines Law and Policy
University Medical Centre Groningen, Global Health Unit, University of Groningen. The Netherlands.

Carlos Correa
Universidad de Buenos Aires
South Centre

Dr. Holger Hestermeyer
Shell Reader in International Dispute Resolution, King's College London

Germán Velásquez
Special Adviser for Health and Development, Switzerland

Professor Yousuf A. Vawda
School of Law, University of Kwazulu-Natal, South Africa

Prof. Dra. Perla Mordujovich-Buschiazzo
Directora Centro
Universitario de Farmacología Centro Colaborador OPS/OMS. Universidad Nacional de La Plata Argentina

James Love
Director
Knowledge Ecology International
USA

Srividhya Ragavan
Professor of Law
Texas A&M Schol of Law
Fort Worth, TX

Dr. V.C. Vivekanandan
Ministry of HRD IP Chair Professor
NALSAR University of Law
Adjunct Visiting Professor, University of Buffalo Business School, New York
Director- Institute of Global Internet Governance & Advocacy (GIGA)-

Wilbert Bannenberg
MD and public health consultant.
Adviser on TRIPS and Access to Medicines to SADC member states

Gawain Kripke
Policy Director
Oxfam America

Susan K. Sell
The George Washington University,
Washington, DC

Cynthia Ho
Loyola University of Chicago School of Law, USA

Matthew B. Flynn
Georgia Southern University

Dr. Ruth Lopert MD MMedSc
FAFPHM
Adjunct Professor Department of Health Policy & Management
Milken Institute School of Public Health
George Washington University

Fran Quigley
Clinical Professor of Law, Director,
Health and Human Rights Clinic
Indiana University McKinney School of Law, USA
Michael Palmedo  
Assistant Director, PIJIP  
American University Washington College of Law

César Rodríguez Garavito  
Centro de Estudios de Derecho, Justicia y Sociedad Dejusticia

Oscar Lizarazo  
Associate Professor  
Faculty of Law National University of Colombia

Dra. Tatiana Andia  
Profesora Universidad de los Andes  
Bogotá Colombia

Jorge Augusto Díaz Rojas.  
Universidad Nacional de Colombia.  
Profesor Asociado  
Colombia.

Carlos H Caicedo E.  
Director del Programa Radial Interacción Emisora UNRADIO 98:5FM  
Bogotá, Colombia Suramérica

Martha Milena Silva Castro. PhD.  
PharmD. MA.  
Teaching and Research Group in Pharmacy Practice.  
University of Barcelona

Martín Cañas  
Cátedra de Farmacología, Instituto de Salud, Universidad Nacional Arturo Jauretche, Argentina

Tahir Amin  
Attorney I-MAK

Gabriel Jaime Otalvaro Castro.  
PhD(c)  
Salud Colectiva Docente Facultad Nacional de Salud Pública  
Universidad de Antioquia, Colombia

Norberto Camacho García  
QF.UN MAE.UN (c)  
Colombia

David G Legge MD  
Professor Emeritus in Public Health  
La Trobe University  
Melbourne, Australia

Gabriel R. Nemogá Ph.D.  
Universidad de Winnipeg - Canadá  
Inv. Int. Grupo de Inv. Política y Legislación en Biodiversidad, Recursos Genéticos y Conocimiento Tradicional  
Universidad Nacional de Colombia

Samuel David Osorio García  
MD colombiano  
Candidato a Maestro en Salud Pública por la Universidad de São Paulo.

Claudia Patricia Vaca González  
Profesora Universidad Nacional De Colombia.

Mario Esteban Hernández Álvarez  
Coordinador Doc. Interfacultades en Salud Pública Universidad Nacional de Colombia.

Luis Jorge Hernández Flórez, MD, PhD  
Profesor Asociado Salud Pública Universidad de los Andes-Facultad de Medicina. Bogotá, Colombia.

Oscar Andia Salazar  
OBSERVAMED-FMC  
Colombia

Rubén Espinoza Carrillo  
Universidad Peruana Cayetano Heredia  
Lima - Perú
Roxana Patricia De las salas Martínez  
Profesora de la Universidad del Norte  
(Barranquilla, Colombia)

Prof. José-Luis Alloza, MD, PhD  
Dep Biomedical Sciences  
School of Medicine and Health Sciences  
The University of Alcalá de Henares  
Spain.

Jorge Costa  
Technologist Oswaldo Cruz Foundation  
– Fiocruz, Brazil

Tatiana Galofre  
Ingeniero Industrial  
Colombia

Shiba Phurailatpam  
Asia Pacific Network of People Living with HIV (APN+)

Maria Auxiliadora Oliveira  
Researcher Oswaldo Cruz Foundation  
– Fiocruz, Brazil

Liliana Sarmiento  
C.C.31158538  
Abogada  
Colombia

Vinciane Servantie  
Administradora de empresas  
Colombia

Andrés Izquierdo  
IP Practicing Attorney  
Washington D.C USA

José Julián López G.  
QF MSc PhD (c)  
Director CIMUN, Fac. de Ciencias,  
Bogotá, Colombia

Gabriela Costa Chaves  
Researcher Oswaldo Cruz Foundation  
– Fiocruz, Brazil

Claudia García Serpa Osorio de Castro  
Researcher Oswaldo Cruz Foundation  
– Fiocruz Brazil

Jorge Machado  
Universidad Tecnológica de Pereira.  
Colombia

Prof. Saúl Franco Agudelo  
Maestría en Salud Pública, Facultad de  
Economía,Universidad Santo Tomás,  
Bogotá, Colombia

Carlos Durán, MD  
Empresa Pública Yachay  
Quito–Ecuador

Vera Lucia Luiza  
Researcher Oswaldo Cruz Foundation  
– Fiocruz  
Brazil

Angela Fernandes Esher Moritz  
Researcher Oswaldo Cruz Foundation  
– Fiocruz  
Brazil

Thiago Botelho Azeredo  
Professor and researcher,  
Federal University of Rio de Janeiro –  
UFRJ

Nina Lisleth Ojeda Sopo  
Universidad Nacional  
Medico

Adriana Mendoza Ruiz  
Researcher Oswaldo Cruz Foundation  
– Fiocruz, Brazil
José Gilberto Orozco Díaz
Profesor Asociado
Universidad Nacional de Colombia
Colombia

Everaldo Lamprea
Professor, Los Andes Law School
everaldolamprea@gmail.com

Giovanny Garavito QF MSc PhD.
Vicedecano Académico (Academic Deputy Dean)
Colombia

Kimberlee Weatherall
Associate Professor Sydney Law School, The University of Sydney

Joan Rovira Forns
Professor Emeritus
Department of Economics, University of Barcelona, Spain

Patrick Durisch
Health Programme Coordinator
Berne Declaration, Switzerland

Karen Hussmann
Public Policies Expert

Dra. María Inés Sarmiento
Docente Fundación Universitaria de Ciencias de la Salud FUCS

Prof. Álvaro Zerda Sarmiento, PhD
Facultad de Ciencias Económicas
Investigador CID, Universidad Nacional de Colombia

Maria Cristina Latorre
Q.F. Sociedad Colombiana de Historia de la Farmacia

Rondineli Mendes da Silva
Researcher Oswaldo Cruz Foundation – Fiocruz, Brazil.

Sergey Kondratyuk
All-Ukrainian Network of PLWA

Yolima Baena Aristizábal
Associate Professor of Pharmacy Department
Universidad Nacional de Colombia

Benoit Marchand, MD
Empresa Pública Yachay
Quito-Ecuador

Adriana Mercedes Ardila Sierra
MD MPH PhD(c)

Claudia Cano Correa
Universidad Externado de Colombia
Colombia

Gabriela Delgado,
profesora asociada, departamento de farmacia
Universidad Nacional de Colombia.

Ulpiana M. Tamayo
Financista
Colombia

Elvia Saenz Botero
Abogada
Colombia

Claudia Lozano Gamba
Abogada
Colombia

Nadia Kahuazango
Politóloga
Colombia

Paula Páez
Especialista en Gobiernos y Relaciones Internacionales. Colombia
David Pinzon
Abogado Colombia

Ricardo Saravia
Servicio de Inf. de Medicamentos de El Salvador CIMES

Carlos Arturo Cadavid V.
Alianza Internacional De Habitantes (AIH) Medellín-Colombia

Xavier Maldonado Dávila
Profesor de la Universidad Central del Ecuador. Coordinador ALAMES núcleo Ecuador

Prof. Martin Uribe Arbeláez
Director del Observatorio de P. I y del Grupo de investigación "Derecho y Desarrollo" Prometeo, adscrito a Unijus Universidad Nacional de Colombia.

Alma de León
Regional Director International Treatment Preparedness Coalition Latin America and The Caribbean "ITPC-LATCA"

María Belén Mena, MD, MPh, PhD (c)
Profesor de Farmacología. Universidad Central del Ecuador.

Camila Gianella Malca
Post Doc fellow CMI, Post doc Fellow University of Bergen, Norway

Kajal Bhardwaj
Lawyer India

Prof. Hernando Gaitán D MD MSc
Gynecology and Obstetrics Department Clinical Research Institute National University of Colombia Co-Ed. Sexually Transmitted Infections Cochrane Review Group

Dr. Kwadwo Appiagyei-Atua
Senior Lecturer School of Law, University of Ghana Legon, Accra, Ghana

Juana Camacho
Instituto Colombiano de Antropología e Historia, Colombia

Jorge Bermúdez
Researcher Oswaldo Cruz Foundation – Fiocruz, Brazil

John T. Mitchell
Interaction Law USA

Tapiwanashe Kujinga
Director Pan-African Treatment Access Movement Africa

Adam Schatten
Hivernation films Boston, MA

Dr. Burcu Kilic
Global Access to medicines Program Public Citizen Washington D.C.

Akbar Noman
Senior Fellow and Adjunct Associate Professor at Columbia University, New York.

Umunyana Rugege
Attorney, SECTION27 South Africa
L Mtima
Law prof at the Howard University
School of Law
USA

Graham Dutfield
Professor of International Governance
School of Law
University of Leeds, UK

Marcela Fogaça Vieira
Coordinator GTPI/Rebrip
Brazil

Juan Pablo Morales
Políticas Farmacéticas
Chile

Pedro Villardi
PhD student in Public Health
IMS/UERJ Brazil

PhD MD Marilena Correa
IMS/UERJ Brazil

Dr. Martin Santos
Región de Salud Central/Ministerio de
Salud El Salvador, C.A.

Dr. Giovanni Francisco Guevara
Director de Tecnologías Sanitarias
Ministerio de Salud de El Salvador

Lorena Di Giano
Fundación Grupo Efecto Positivo-
Argentina.
RedLAM
Argentina

Angélica Garzón Umerenkova
Docente-investigadora Universidad El
Bosque
Bogotá, Colombia

Germán Humberto Rincón Perfetti
Rincón Perfetti Abogados &
Consultores Internacionales
Asociación Líderes en Acción
Bogotá, Colombia